Interferon‐free therapy for genotype 1 hepatitis C in liver transplant recipients: Real‐world experience from the hepatitis C therapeutic registry and research network
Robert S. Brown(Columbia University Irving Medical Center), Norah A. Terrault(University of California, San Francisco), Christine M. Durand(Johns Hopkins University), Thomas G. Stewart(University of North Carolina at Chapel Hill), Adrian M. Di Bisceglie, Paul Y. Kwo(Indiana University School of Medicine), James R. Burton(University of Colorado Denver), K. Rajender Reddy(University of Pennsylvania Health System), R. Todd Stravitz(Virginia Commonwealth University), Jacqueline G. O’Leary(Baylor University Medical Center), David R. Nelson(University of Florida), Giuseppe Morelli(University of Florida), Catherine Frenette(Scripps Clinic), Michael Fried(University of North Carolina at Chapel Hill), Alexander Kuo(University of California San Diego)
Cited by 105
Related Papers
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
|New England Journal of Medicine|2002|3.3k
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
|The Lancet|2014|2.2k
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
|New England Journal of Medicine|2013|1.8k
Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma
|JNCI Journal of the National Cancer Institute|2008|1.7k
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
|New England Journal of Medicine|2014|1.1k